Invex Therapeutics (ASX:IXC) Other Current Receivables: A$0.00 Mil (As of Dec. 2025)


What is Invex Therapeutics Other Current Receivables?

Invex Therapeutics ASX:IXC Other Current Receivables is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Other Current Receivables for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics's annual Other Current Receivables declined from Jun. 2023 (A$0.33 Mil) to Jun. 2024 (A$0.10 Mil) and declined from Jun. 2024 (A$0.10 Mil) to Jun. 2025 (A$0.09 Mil).

Invex Therapeutics Other Current Receivables Related Terms

Invex Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Other Current Receivables Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial 0.02 0.15 0.33 0.10 0.09

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.10 0.00 0.09 0.00

Invex Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Other Current Receivables of A$0.00 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Other Current Receivables too high?
Invex Therapeutics' current Other Current Receivables is A$0.00 Mil.
How does Invex Therapeutics' Other Current Receivables compare to VRTX and REGN?
Invex Therapeutics' Other Current Receivables of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Other Current Receivables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Other Current Receivables of A$0.00 Mil. The current Other Current Receivables is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Other Current Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.